Selumetinib was found to have an inhibitory effect on S6 activation after 24h treatment in an earlier study on BRAF mutant melanoma cell lines [57], which may contribute to the enhanced effect of the combination when compared to single treatment. The gene discussed is BRAF; the disease is melanoma.